Obesity in menopause - our negligence or an unfortunate inevitability?

Jarosław Kozakowski, Małgorzata Gietka-Czernel, Dorota Leszczyńska, Agnieszka Majos, Jarosław Kozakowski, Małgorzata Gietka-Czernel, Dorota Leszczyńska, Agnieszka Majos

Abstract

Numerous concerns about menopause exist among women, and fear of an increase in body weight is one of the most important of them. This paper presents an overview of current knowledge concerning the etiology of obesity related to menopause and about the mechanisms of its development, with particular regard to the hormonal changes that occur during this period of life. The role of estrogens in the regulation of energy balance and the effect of sex hormones on metabolism of adipose tissue and other organs are presented. The consequence of the sharp decline in the secretion of estrogens with subsequent relative hyperandrogenemia is briefly discussed. The main intention of this review is to clarify what is inevitable and what perhaps results from negligence and unhealthy lifestyles. In the last part of the paper the possibilities of counteracting the progress of adverse changes in body composition, by promoting beneficial lifestyle modifications and the use of hormonal substitution treatment, in cases where it is reasonable and possible, are described.

Keywords: cardiovascular risk; menopause; metabolic syndrome; obesity.

References

    1. Kwaśniewska M, Pikala M, Kaczmarczyk-Chałas K, et al. Smoking status, the menopausal transition, and metabolic syndrome in women. Menopause. 2012;19:194–200.
    1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. J Am Med Ass. 2010;303:235–241.
    1. Stefańska A, Bergmann K, Sypniewska G. Metabolic Syndrome and Menopause: Patophysiology, Clinical and Diagnostic Significance. Adv Clin Chem. 2015;72:1–75.
    1. Donato GB, Fuchs SC, Oppermann K, et al. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause. 2006;13:280–285.
    1. Panotopoulos G, Raison J, Ruiz JC, et al. Weight gain at the time of menopause. Hum Reprod. 1997;12(Suppl 1):126–133.
    1. Luglio HF. Estrogen and body weight regulation in women: the role of estrogen receptor alpha (ER-α) on adipocyte lipolysis. Acta Med Indones. 2014;46:333–338.
    1. Pedersen SB, Kristensen K, Hermann PA, et al. Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab. 2004;89:1869–1878.
    1. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol. 2010;122:74–81.
    1. Toth MJ, Sites CK, Eltabbakh GH, et al. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care. 2000;23:801–806.
    1. Davis SR, Robinson PJ, Moufarege A, et al. The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women. Clin Endocrinol (Oxf) 2012;77:541–547.
    1. Carr MC. The Emergence of the Metabolic Syndrome with Menopause. J Clin Endocrinol Metab. 2003;88:2404–2411.
    1. Kalyani RR, Franco M, Dobs AS, et al. The Association of Endogenous Sex Hormones, Adiposity, and Insulin Resistance with Incident Diabetes in Postmenopausal Women. J Clin Endocrinol Metabl. 2009;94:4127–4135.
    1. Piché M-E, Weisnagel SJ, Corneau L, et al. Contribution of Abdominal Visceral Obesity and Insulin Resistance to the Cardiovascular Risk Profile of Postmenopausal Women. Diabetes. 2005;54:770–777.
    1. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN) Circulation. 2005;111:1242–1249.
    1. Barros RP, Gabbi C, Morani A, et al. Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. Am J Physiol Endocrinol Metab. 2009;297:E124–133.
    1. Frank A, Lynda M, Brown LM, et al. The Role of Hypothalamic Estrogen Receptors in Metabolic Regulation. Front Neuroendocrinol. 2014;35:550–557.
    1. Tworoger SS, Mantzoros C, Hankinson SE. Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels. Obesity (Silver Spring) 2007;15:2217–2224.
    1. Monteiro R, Teixeira D, Calhau C. Estrogen Signaling in Metabolic Inflammation. Mediators Inflamm. 2014;2014:615917.
    1. Shelley JM, Green A, Smith AM, et al. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol. 1998;8:39–45.
    1. Maas AHEM, Franke HR. Women’s health in menopause with a focus on hypertension. Neth Heart J. 2009;17:68–72.
    1. Reslan OM, Khalil RA. Vascular Effects of Estrogenic Menopausal Hormone Therapy. Rev Recent Clin Trials. 2012;7:47–70.
    1. Nestor CC, Kelly MJ, Rønnekleiv OK. Cross-talk between reproduction and energy homeostasis: central impact of estrogens, leptin and kisspeptin signaling. Horm Mol Biol Clin Investig. 2014;17:109–128.
    1. Rebouças EC, Leal S, Sá SI. Regulation of NPY and α-MSH expression by estradiol in the arcuate nucleus of Wistar female rats: a stereological study. Neurol Res. 2016;38:740–747.
    1. Dafopoulos K, Chalvatzas N, Kosmas G, et al. The effect of estrogens on plasma ghrelin concentrations in women. J Endocrinol Invest. 2010;33:109–112.
    1. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–941.
    1. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
    1. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8:538–554.
    1. Samaras K, Hayward CS, Sullivan D, et al. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care. 1999;22:1401–1407.
    1. Millen BE, Pencina MJ, Kimokoti RW, et al. Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. Am J Clin Nutr. 2006;84:434–441.
    1. Neuhouser ML, Howard B, Lu J, et al. A low-fat dietary pattern and risk of metabolic syndrome in postmenopausal women: the Women’s Health Initiative. Metabolism. 2012;61:1572–1581.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren